Cargando…

MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction

BACKGROUND: Mid-regional pro-atrial natriuretic peptide (MR-proANP) is a useful biomarker in outpatients with type 2 diabetes (T2D) to diagnose heart failure (HF). Elevated B-type natriuretic peptides are included in the definition of HF with preserved ejection fraction (HFpEF) but little is known a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Jesper, Schou, Morten, Kistorp, Caroline, Faber, Jens, Hansen, Tine W., Jensen, Magnus T., Andersen, Henrik U., Rossing, Peter, Vilsbøll, Tina, Jørgensen, Peter G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568388/ https://www.ncbi.nlm.nih.gov/pubmed/33066783 http://dx.doi.org/10.1186/s12933-020-01155-9

Ejemplares similares

Dataset of the associations of aldosterone to renin ratio with MR-proANP and MR-proADM
por: Then, Cornelia, et al.
Publicado: (2016)

MR-proADM and MR-proANP levels in patients with acute pulmonary embolism
por: Öner, Önsel, et al.
Publicado: (2020)

Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP
por: Behnes, Michael, et al.
Publicado: (2017)

Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients
por: Yagmur, Eray, et al.
Publicado: (2019)

Comparative accuracy of NT‐proBNP and MR‐proANP for the diagnosis of acute heart failure in dyspnoeic patients
por: Darche, Fabrice F., et al.
Publicado: (2017)

Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1)
por: Gerull, Roland, et al.
Publicado: (2021)

Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model
por: Cirera, Susanna, et al.
Publicado: (2013)

Isolated Insular Strokes and Plasma MR-proANP Levels Are Associated with Newly Diagnosed Atrial Fibrillation: A Pilot Study
por: Frontzek, Karl, et al.
Publicado: (2014)

ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study
por: Lauridsen, Bo K, et al.
Publicado: (2013)

Response to the Letter: The NT‐proANP puzzle ‐ a small piece that makes the big picture
por: Seewöster, Timm, et al.
Publicado: (2020)

FTIR Analysis of Renal Tissue for the Assessment of Hypertensive Organ Damage and proANP(31–67) Treatment
por: Pioppi, Leonardo, et al.
Publicado: (2023)

Short‐Term Influence of Radiofrequency Ablation on NT‐proBNP, MR‐proANP, Copeptin, and MR‐proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study
por: Charitakis, Emmanouil, et al.
Publicado: (2016)

Assessment of the left atrial volume index and plasma NT-proANP level in patients with acute ST-elevation myocardial infarction
por: Bacaksiz, Ahmet, et al.
Publicado: (2013)

Polymorphism in NEDD4L Is Associated with Increased Salt Sensitivity, Reduced Levels of P-renin and Increased Levels of Nt-proANP
por: Dahlberg, Jonas, et al.
Publicado: (2007)

Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure
por: Miller, Wayne L, et al.
Publicado: (2011)

Association Between Cardiovascular Magnetic Resonance‐Derived Left Atrial Dimensions, Electroanatomical Substrate and NT‐proANP Levels in Atrial Fibrillation
por: Seewöster, Timm, et al.
Publicado: (2018)

Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with reduced NT-proANP, increased stroke and higher diastolic blood pressure
por: Pereira, Naveen L, et al.
Publicado: (2015)

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes
por: Christensen, Regitse H., et al.
Publicado: (2019)

Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus
por: Jørgensen, Peter Godsk, et al.
Publicado: (2018)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes
por: Jørgensen, Peter Godsk, et al.
Publicado: (2016)

The prognostic role of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio and its relationship with NT-proANP plasma level in systemic sclerosis
por: Grimaldi, Maria Chiara, et al.
Publicado: (2023)

ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
por: Brandt-Jacobsen, Niels, et al.
Publicado: (2022)

Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
por: Brandt‐Jacobsen, Niels H., et al.
Publicado: (2023)

Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study
por: Jensen, Jesper, et al.
Publicado: (2023)

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
por: Omar, Massar, et al.
Publicado: (2022)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
por: Jürgens, Mikkel, et al.
Publicado: (2021)

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction
por: Christensen, Heidi M, et al.
Publicado: (2013)

Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation
por: Refsgaard Holm, Maria, et al.
Publicado: (2019)

Mechanisms for the secretion of ANP.
por: Cho, K. W., et al.
Publicado: (1997)

Hypoglycaemia and cardiac arrhythmias in diabetes
por: Andersen, Andreas, et al.
Publicado: (2020)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
por: Rasmussen, Jon Jarløv, et al.
Publicado: (2016)

Effect of Shading on Red Colour and Fruit Quality in Blush Pears “ANP-0118” and “ANP-0131”
por: Peavey, Madeleine, et al.
Publicado: (2020)

Prognostic utility of diastolic dysfunction and speckle tracking echocardiography in heart failure with reduced ejection fraction
por: Hansen, Sune, et al.
Publicado: (2019)

Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial
por: H. Brandt-Jacobsen, Niels, et al.
Publicado: (2023)

MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail
por: Kistorp, Caroline, et al.
Publicado: (2019)

High Intensity Exercises in Heart Failure with Preserved Ejection Fraction
por: Herdy, Artur Haddad, et al.
Publicado: (2018)

ANP mutation causes reduced proteolysis
por: Dickey, Deborah M, et al.
Publicado: (2009)

Dual actions of ANP on endothelial permeability
por: Chen, Wen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j2ikpq5mpmacnmmpln5e68r6ar